Palliative Radiotherapy Reduces End-Stage Liver Cancer Pain Palliative Radiotherapy Reduces End-Stage Liver Cancer Pain
Most patients with end-stage hepatocellular carcinoma experience pain; a new study shows that low-dose radiotherapy can relieve pain and even improve survival.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 26, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

PSMA-PET matches MRI, beats CT in diagnosing liver cancer
Prostate-specific membrane antigen (PSMA) PET/CT appears equivalent to MRI an...Read more on AuntMinnie.comRelated Reading: CT radiomics helps predict HCC recurrence after liver transplant New tracer bests FDG for diagnosing liver cancer PET identifies early responders to liver cancer treatment AI can identify hepatocellular carcinoma on liver CT exams (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 23, 2023 Category: Radiology Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Investor Update - January 19, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Media News - January 19, 2023 Category: Pharmaceuticals Source Type: news

Holistic Management Of Hepatocellular Carcinoma Holistic Management Of Hepatocellular Carcinoma
The authors highlight the need for a team-based holistic approach to the patient with hepatocellular carcinoma, presenting a practical playbook for management of patients with liver disease and HCC.Liver International (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - January 6, 2023 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news

Liver Cancer Exacts High Financial Toll on Older Adults Liver Cancer Exacts High Financial Toll on Older Adults
The financial burden of hepatocellular carcinoma, the most common type of liver cancer, is high for Medicare beneficiaries in the first year after diagnosis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2022 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news

Phase III results show Roche's subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes
Administered under the skin, the subcutaneous formulation reduces time spent receiving treatment to approx. seven minutes, compared with 30-60 minutes for IV infusion1Roche has submitted data from the IMscin001 study to health authorities, seeking approval for the subcutaneous option across all approved indications of IVTecentriq  If approved,Tecentriq would be Roche ’s fourth subcutaneous cancer therapy,2-4 helping to improve the treatment experience for patients. In addition, it could save resources for healthcare systems5-10Basel, 1 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new pivotal data ...
Source: Roche Investor Update - December 1, 2022 Category: Pharmaceuticals Source Type: news

Robotic Resection Cuts Perioperative Morbidity With Liver Cancer
MONDAY, Nov. 28, 2022 -- Robotic liver resection (RLR) is associated with a significant reduction in perioperative morbidity for treatment of hepatocellular carcinoma (HCC) versus open-liver resection (OLR), according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 28, 2022 Category: Pharmaceuticals Source Type: news

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Radiotherapy Improves Survival in Difficult Liver Cancer Cases Radiotherapy Improves Survival in Difficult Liver Cancer Cases
Stereotactic body radiotherapy plus sorafenib led to a strong survival benefit vs sorafenib alone in advanced hepatocellular carcinoma.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 31, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma
On October 21, 2022, the Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). ​​​​​​​ (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 24, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Imjudo (tremelimumab) in Combination with Imfinzi for Patients with Unresectable Hepatocellular Carcinoma
24 October 2022 -- AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 24, 2022 Category: Drugs & Pharmacology Source Type: news

Antiviral Therapy Improves Survival After Liver Cancer Surgery Antiviral Therapy Improves Survival After Liver Cancer Surgery
The analysis focused on elderly patients after hepatectomy for hepatitis B virus –related hepatocellular carcinoma. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 20, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

HCC 10+ Years After Viral Eradication in Patients With HCV HCC 10+ Years After Viral Eradication in Patients With HCV
What risk factors are associated with hepatocellular carcinoma development 10 years or more after SVR?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 7, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Liver Cancer Risk May Rise for 2nd - , 3rd - Generation U.S. Mexicans
Risk of hepatocellular carcinoma increased by 35 and 61 percent for second - , third - versus first - generation U.S. Mexicans (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 20, 2022 Category: Cancer & Oncology Tags: Gastroenterology, Internal Medicine, Oncology, Conference News, Source Type: news